Inovio, GeneOne plan clinical study of Zika vaccine

Inovio Pharmaceuticals Inc. (NASDAQ:INO) and GeneOne Life Science Inc. (KSE:011000) said they plan to start an open-label Phase I study "in the next weeks" of GLS-5700, their vaccine to prevent Zika virus infection. This year, the partners expect interim data from the dose-ranging study, which is to enroll about 40 healthy volunteers.

GLS-5700 consists of synthetic DNA vaccine constructs targeting multiple Zika virus antigens administered using Inovio's Cellectra electroporation technology. ...